Tryptamine Therapeutics (ASX:TYP) completed the dosing of the first subject in its phase 1b study of its lead asset, TRP-8803, in obese participants, according to a Friday filing with the Australian bourse.
TRP-8803 is an intravenous-infusion formulation containing psilocin, known for its ability to induce adaptive structural and functional changes within the brain, the filing said.
The first participant received the drug, safely progressed through treatment, and was discharged shortly after the dosing follow-up was completed, according to the filing. Two more study applicants will be given TRP-8803 in the coming weeks.
Tryptamine Therapeutics shares rose more than 2% in afternoon trade Friday.
Price (AUD): $0.05, Change: $+0.001, Percent Change: +2.22%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。